<DOC>
	<DOCNO>NCT00696956</DOCNO>
	<brief_summary>The study perform randomize , double blind trial ( respect primary end point ) treatment stenotic lesion use uncoated PTA-catheters control group . 114 patient include trial 5 study center . Follow-up include control angiography 6 18 month clinical follow-up examination 18 month . Primary objective : Efficacy paclitaxel coat PTA balloon inhibit restenosis knee artery ( late lumen loss ) Secondary objective : Various angiographic clinical efficacy measure , safety tolerance pacli-taxel coated PTA balloon inhibit restenosis knee artery Descriptive statistic , comparison t-test , chi-square test binary event 10.1 Descriptive statistic As far applicable descriptive statistic apply data refer individual change versus baseline ( predilatation immediately postdilatation ) . The group compare test statistical significance difference ( p ≤ 0.05 ) . Con-tinuous data express mean ± standard deviation . Categorical variable compare use chi-squared test , continuous variable compare use Student 's test ANOVA analysis . In addition assessment primary endpoint secondary endpoint multi-variate analysis investigate influence risk factor interventional outcome ( interventional success , early restenosis/occlusion , LLL , stent integrity ) clinical outcome perform . For analysis follow factor consider : age , diabetes , neurological status ( Rutherford 5 ) , lesion length , grade dissection calcification , reststenosis , number run-off vessel , stent administration index lesion ( ) . 10.2 Estimated number patient The primary endpoint study late lumen loss ( LLL ) 6 month evaluate quantitative angiography . Because data accord endpoint available control group group treat paclitaxel coat balloon assumption accord LLL 6 month make accord expectation principle investigator . An estimate LLL % MLD control group 50 % drug coat balloon group 30 % . The standard deviation calculate 30 % LLL . A sample size 37 patient group allow detection statistically significant difference ( p &lt; 0.05 ) 80 % power . Based `` Below study '' enrol patient comparable arterial lesion Tuebingen data Basil study , estimate 35 % patient enrol study available follow-up investigation order calculate MLD . In order meet statistical endpoint total 114 patient enrol .</brief_summary>
	<brief_title>Drug Coated Balloons Prevention Restenosis</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age 18 95 year , peripheral vascular disease , Rutherford stage 35 , diameter stenosis ≥ 70 % , ≥ 15 150 mm length , 2 vessel treat Disease associate lifeexpectancy le 18 month Acute thrombus aneurysm index limb/ vessel Doubts willingness capability patient allow follow examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>local drug delivery</keyword>
	<keyword>balloon angioplasty</keyword>
	<keyword>safety tolerance paclitaxel coat PTA balloon</keyword>
	<keyword>inhibit restenosis knee artery</keyword>
	<keyword>Efficacy paclitaxel coat PTA balloon</keyword>
	<keyword>inhibit restenosis knee artery ( late lumen loss )</keyword>
</DOC>